A detailed history of Hrt Financial LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Hrt Financial LP holds 4,434 shares of BGNE stock, worth $851,815. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,434
Holding current value
$851,815
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$143.93 - $224.51 $638,185 - $995,477
4,434 New
4,434 $995,000
Q4 2021

Feb 14, 2022

SELL
$248.56 - $389.34 $182,691 - $286,164
-735 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$249.6 - $403.14 $183,456 - $296,307
735 New
735 $266,000
Q2 2020

Aug 14, 2020

SELL
$123.9 - $195.41 $221,161 - $348,806
-1,785 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$121.84 - $173.19 $217,484 - $309,144
1,785 New
1,785 $219,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.9B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.